QS Investors’s Global Blood Therapeutics, Inc. GBT Stock Holding History

QS Investors’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-1,500	Closed	-$95K	–	1614
2020 Q2	$95K	Hold	1,500	–	–	﹤0.01%	1339
2020 Q1	$77K	Hold	1,500	–	–	﹤0.01%	1330
2019 Q4	$118K	Hold	1,500	–	–	﹤0.01%	1340
2019 Q3	$73K	Hold	1,500	–	–	﹤0.01%	1442
2019 Q2	$79K	Sell	1,500 -1,800	-55%	-$103K	﹤0.01%	1441
2019 Q1	$175K	Buy	+3,300	New	+$162K	﹤0.01%	1260
2018 Q4	–	Sell	-1,100	Closed	-$42K	–	1944
2018 Q3	$42K	Hold	1,100	–	–	﹤0.01%	1499
2018 Q2	$50K	Hold	1,100	–	–	﹤0.01%	1517
2018 Q1	$53K	Buy	+1,100	New	+$61.4K	﹤0.01%	1469

Other funds holding GBT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

QS Investors's GBT Position: Q3 2020 in Review

QS Investors sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2020, closing a stake of 1,500 shares — an estimated $95K sold.

QS Investors first reported a position in GBT in Q1 2018 and held it in 9 quarters. The position peaked at $175K in Q1 2019. 229 funds tracked by Wall St. Rank hold GBT as of Q3 2020.

QS Investors reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2020 after selling out during the quarter.
QS Investors sold 1,500 Global Blood Therapeutics, Inc. shares in Q3 2020, an estimated $95K.
QS Investors first reported a position in Global Blood Therapeutics, Inc. in Q1 2018 and held it in 9 quarters.
QS Investors's Global Blood Therapeutics, Inc. position peaked at $175K in Q1 2019.
229 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2020.

Based on QS Investors's 13F filing for Q3 2020, filed 12 Nov 2020.